|Tetrandrine blocks cardiac hypertrophy by disrupting reactive oxygen species-dependent ERK1/2 signalling.|
|PMID: 20105174 Owner: NLM Status: MEDLINE|
|BACKGROUND AND PURPOSE: Tetrandrine, a well-known naturally occurring calcium antagonist with anti-inflammatory, antioxidant and anti-fibrogenetic activities, has long been used clinically for treatment of cardiovascular diseases such as hypertension and arrhythmia. However, little is known about the effect of tetrandrine on cardiac hypertrophy. The aims of the present study were to determine whether tetrandrine could attenuate cardiac hypertrophy and to clarify the underlying molecular mechanisms.
EXPERIMENTAL APPROACH: Tetrandrine (50 mg x kg(-1) x day(-1)) was administered by oral gavage three times a day for one week and then the mice were subjected to either chronic pressure overload generated by aortic banding (AB) or sham surgery (control group). Cardiac function was determined by echocardiography.
KEY RESULTS: Tetrandrine attenuated the cardiac hypertrophy induced by AB, as assessed by heart weight/body weight and lung weight/body weight ratios, cardiac dilatation and the expression of genes of hypertrophic markers. Tetrandrine also inhibited fibrosis and attenuated the inflammatory response. The cardioprotective effects of tetrandrine were mediated by blocking the increased production of reactive oxygen species and the activation of ERK1/2-dependent nuclear factor-kappaB and nuclear factor of activated T cells that occur in response to hypertrophic stimuli.
CONCLUSIONS AND IMPLICATIONS: Taken together, our results suggest that tetrandrine can improve cardiac function and prevent the development of cardiac hypertrophy by suppressing the reactive oxygen species-dependent ERK1/2 signalling pathway.
|Di-Fei Shen; Qi-Zhu Tang; Ling Yan; Yan Zhang; Li-Hua Zhu; Lang Wang; Chen Liu; Zhou-Yan Bian; Hongliang Li|
Related Documents :
|8762044 - Cyclic amp-dependent protein kinase and mechanical heart function in ventricular hypert...
19074594 - The effects of candesartan on left ventricular hypertrophy and function in nonobstructi...
2886234 - Effects of chronic progressive myocardial hypertrophy on indexes of cardiac autonomic i...
6446744 - Turnover rates and synthesis of cardiac structural proteins in normal and hypertrophied...
2969254 - Raised concentrations of glucose and adrenaline and increased in vivo platelet activati...
10866244 - Identification of trauma patients at risk of thoracic aortic tear by mechanism of injury.
|Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2010-01-25|
|Title: British journal of pharmacology Volume: 159 ISSN: 1476-5381 ISO Abbreviation: Br. J. Pharmacol. Publication Date: 2010 Feb|
|Created Date: 2010-04-14 Completed Date: 2010-07-09 Revised Date: 2011-07-22|
Medline Journal Info:
|Nlm Unique ID: 7502536 Medline TA: Br J Pharmacol Country: England|
|Languages: eng Pagination: 970-81 Citation Subset: IM|
|Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China.|
|APA/MLA Format Download EndNote Download BibTex|
Anti-Inflammatory Agents / pharmacology
Antioxidants / pharmacology
Benzylisoquinolines / administration & dosage, pharmacology*
Cardiomegaly / enzymology, etiology, physiopathology, prevention & control*, ultrasonography
Cardiotonic Agents / administration & dosage, pharmacology*
Disease Models, Animal
Heart Failure / complications, drug therapy*, enzymology, physiopathology, ultrasonography
Mitogen-Activated Protein Kinase 1 / metabolism*
Mitogen-Activated Protein Kinase 3 / metabolism*
Myocytes, Cardiac / drug effects*, enzymology, pathology
NF-kappa B / genetics, metabolism
NFATC Transcription Factors / genetics, metabolism
Reactive Oxygen Species / metabolism*
Recovery of Function
Signal Transduction / drug effects*
Ventricular Function, Left / drug effects
|0/Anti-Inflammatory Agents; 0/Antioxidants; 0/Benzylisoquinolines; 0/Cardiotonic Agents; 0/NF-kappa B; 0/NFATC Transcription Factors; 0/Reactive Oxygen Species; 518-34-3/tetrandrine; EC 22.214.171.124/Mitogen-Activated Protein Kinase 1; EC 126.96.36.199/Mitogen-Activated Protein Kinase 3|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Narrow-band UVB course improves vitamin D balance in women in winter.
Next Document: Bidirectional modulation of isoflurane potency by intrathecal tetrodotoxin and veratridine in rats.